Sostravel.com receives a research report by Arrowhead detailing a 2.76x potential upside in price
Sostravel.com S.p.A. (Euronext Growth Milan, ticker: SOS), digital operator offering booking services, digital itineraries including information on flights and airports, car rental, experiences, and proprietary services including the Lost Luggage Concierge through the Sostravel and Flio apps, as well as through the platforms www.Sostravel.com and www.amareitalia.com, announces that today, Arrowhead, an Independent Research company based in New York, providing due diligence and valuation reports on selected listed companies, published a research report on Sostravel, with a Fair Share Valuation Bracket of 2.01 to 2.50 EUR, when the share price of the company (ticker BIT: SOS) trades at ~0.90 EUR, for a 2,760% potential appreciation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221115006003/en/
Sostravel App offers booking services, digital itineraries including flight and airport information, car renting, experiences, and insurance services. The company operates the Lost Luggage Concierge proprietary service and is expanding into telehealth services designed for travellers. (Graphic: Business Wire)
Sostravel.com S.p.A. (SOS), headquartered in Italy, operates in the global travel and tourism (T&T) industry. It has a presence online, on Google Play, and Apple App Store, and in 23 airports in Europe, America, and Asia. The company was founded in 2017 as a spin-off from TraWell Co. (previously Safe Bag).
On November 1st, the company finalized the merger with DDC, a company with strong expertise in digital marketing for traveling and an established booking platform. The app, now merged with DDC allows customers to engage in bookings of airplanes, hotels, and cars, build a digital itinerary with other services, such as tours and events, and access value-added services like Lost Luggage Concierge and telehealth. The strategy is to attract potential customers with booking services and offer high-margin services through the app, focusing on the leisure and holiday segments.
The new post-merger entity is positioned to capture the growth in digital travel revenues, already owning a significant share of the passenger information sector, Sostravel aims to consolidate the world of traveler information and services, with the only integrated app on the market.
Based on its due diligence and valuation estimates, Arrowhead believes that SOS’s fair share value lies in the EUR 2 to EUR 2.50 bracket, which has been calculated using a blended valuation method: with 60% weighting to a discounted cash flow (DCF) method and 40% weighting to a Comparable Companies Valuation method.
Sostravel is listed on Euronext Growth Milan, ticker BIT: SOS
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221115006003/en/
Contact information
For further information:
Sostravel.com S.p.A.
Investor Relations
Edoardo Zarghetta
investor.relations@Sostravel.com
www.Sostravel.com
Ph: +39 0331 1587117
Fax: +39 0331 1582452
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabGenius Therapeutics Announces Poster Presentation at the ESMO Immuno-Oncology Congress 202513.11.2025 02:00:00 EET | Press release
LabGenius Therapeutics (“LabGenius”), a drug discovery company combining artificial intelligence (AI) and high-throughput experimentation to advance next-generation multispecific antibodies for solid tumours, today announced a scientific poster will be presented at the ESMO Immuno-Oncology Congress 2025, being held December 10 - 12, 2025, at the Queen Elizabeth II Centre in London, United Kingdom. LabGenius’ presentation will debut the pre-clinical in vivo efficacy (>90% tumour growth inhibition) and tolerability data for their lead asset, a highly tumour selective bispecific T-cell engager (TCE). Poster Presentation Details Title Novel Selectivity-Enhanced Bispecific T-cell Engager Utilises Avidity to Overcome On-target, Off-tumour Toxicity Date and time Wednesday, December 10, 2025, 08:00 (GMT) Poster number 309P Location The Churchill Room, Queen Elizabeth II Centre, London Bispecific TCE Overview For the selected target, LabGenius has developed a selectivity-enhanced TCE. The compa
VeriSilicon and Google Jointly Launch Open-Source Coral NPU IP13.11.2025 02:00:00 EET | Press release
VeriSilicon (688521.SH) recently announced the joint launch of the Coral NPU IP with Google, targeting always-on, ultra-low-energy edge Large Language Model (LLM) applications. The IP is based on Google’s foundational research in open machine learning compilers and enhanced with AI security features, providing developers with a unified open-source platform to build a robust edge AI ecosystem. The Coral NPU is built on the open RISC-V instruction set architecture, featuring native tensor processing capabilities, supporting mainstream machine learning frameworks such as JAX, PyTorch, and TensorFlow Lite (TFLite), and utilizing open-standard tools like Multi-Level Intermediate Representation (MLIR) from the Low Level Virtual Machine (LLVM) project for compiler infrastructure. It is designed for always-on, ultra-low-energy edge AI applications, particularly for wearable devices and ambient sensing systems. The Coral NPU IP is now open-sourced on the Google Developers website and available
Indero Announces Breakthrough Method for Early-Phase Evaluation of Topical Drugs Using Quantitative Gene Expression13.11.2025 01:00:00 EET | Press release
Indero is proud to announce the successful completion of an internally funded study that introduces a novel approach to evaluating topical new chemical entities (NCE) in early-phase clinical research. This innovative method leverages quantitative gene expression analysis to assess drug efficacy rapidly and cost effectively. Dr. Robert Bissonnette, Executive Chairman and Founder of Indero, who initiated and led the study, shared his excitement about the results: “Our goal was to rethink how to study topical drugs in early phase studies. The results of this study demonstrate that microdosing for only 3 days can provide meaningful efficacy signals. Within just 24 hours, we observed alterations in gene expression after applying a microdose of mid-potency corticosteroid on the skin of patients. By 72 hours, Th2, Th22 and Th17-specific biomarkers were significantly reduced. This outcome is exactly what we hoped for and opens the door to faster, smarter drug development strategies, demonstrat
Valorem Reply recognized as Winner of 2025 Microsoft Inclusion Changemaker Partner of the Year12.11.2025 22:30:00 EET | Press release
Valorem Reply, the Reply Group company specializing in Microsoft technologies and AI-driven, cloud-native solutions, announced today it has won the 2025 Microsoft Inclusion Changemaker Partner of the Year Award. The company was honored among a global field of top Microsoft partners for demonstrating excellence in innovation and implementation of customer solutions based on Microsoft technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112917859/en/ The Inclusion Changemaker Partner of the Year Award celebrates partners that lead with inclusive design, accessibility, and innovation to help customers and communities achieve more. “We’re proud of Valorem Reply for earning this recognition,” said Filippo Rizzante, CTO at Reply. “Their work exemplifies our shared commitment to inclusion and to using technology as a catalyst for opportunity and meaningful change. This award reflects the dedication and creativity of the Va
TOURISE 2025 Debuts Agentic Tourism Initiative, Pioneering the Protocol for Intelligent Travel12.11.2025 22:25:00 EET | Press release
The Agentic Tourism Initiative was unveiled today at the inaugural TOURISE Summit, introducing the world’s first Agentic Protocol for Tourism, a universal digital framework set to transform every stage of the traveler’s journey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112353634/en/ His Excellency Ahmed Al Khateeb, Saudi Arabia's Minister of Tourism and Chairman of TOURISE, launches the Agentic Tourism Initiative on the second day of TOURISE. Launched in partnership with TOURISE and Globant, the Initiative builds on the momentum of the acclaimed whitepaper Tourism’s AI Takeover: Reinventing Travel through Agentic Tourism to create a landmark application of AI. It directly answers the whitepaper’s call to create an Open Protocol for Tourism AI, defining how AI agents interact from inspiration to return. The result: intelligent, seamless, and sustainable travel experiences across the global tourism ecosystem. The Init
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom